KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Non Operating Income: 2020-2024

Historic Non Operating Income for Xenon Pharmaceuticals (XENE) over the last 5 years, with Dec 2024 value amounting to $40.9 million.

  • Xenon Pharmaceuticals' Non Operating Income fell 42.11% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.1 million, marking a year-over-year decrease of 25.45%. This contributed to the annual value of $40.9 million for FY2024, which is 30.32% up from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Non Operating Income stood at $40.9 million for FY2024, which was up 30.32% from $31.4 million recorded in FY2023.
  • Over the past 5 years, Xenon Pharmaceuticals' Non Operating Income peaked at $40.9 million during FY2024, and registered a low of $105,000 during FY2021.
  • Over the past 3 years, Xenon Pharmaceuticals' median Non Operating Income value was $31.4 million (recorded in 2023), while the average stood at $25.4 million.
  • Per our database at Business Quant, Xenon Pharmaceuticals' Non Operating Income plummeted by 95.24% in 2021 and then skyrocketed by 3,602.86% in 2022.
  • Xenon Pharmaceuticals' Non Operating Income (Yearly) stood at $2.2 million in 2020, then tumbled by 95.24% to $105,000 in 2021, then soared by 3,602.86% to $3.9 million in 2022, then skyrocketed by 706.82% to $31.4 million in 2023, then surged by 30.32% to $40.9 million in 2024.